PharmaTalkRadio

Latest Episodes:

R&D Veteran Keynote, Dr Jo Viney, from Chief Medical Officer Summit 360° 2021 Feb 17, 2022

Show notes

Dr Viney joined the CMO Summit 360° in October 2021 to share her incredible journey in drug discovery and development, founding and leading Pandion Therapeutics and joining the advisory boards of multiple biotech companies. Learn more about the 10th annual CMO Summit 360° taking place April 4-5, 2022 here.

Biotech CEO Keynote, Dr Ron Cohen, from Chief Medical Officer Summit 360° 2021 Feb 17, 2022

Show notes

In this podcast, hear a keynote session from the 2021 Chief Medical Officer Summit 360˚ with Dr Ron Cohen on his journey founding and building Acorda Therapeutics and leading the company as an MD CEO for 26 years. Dr Cohen also shares advice on how CMOs can best collaborate with their CEOs and add value to their companies. Learn more about the 10th annual Chief Medical Officer Summit taking place April 4-5, 2022 here.

10th Annual Chief Medical Officer Summit 360º in a Nutshell Feb 15, 2022

Show notes

Conference Producer, Andrew Goldstein, walks through what you can expect to learn and who you'll hear from at the upcoming Chief Medical Officer Summit 360º taking place April 4-5, 2022 in Boston, MA, including: Clinical development and operationsRelationships within the C-suite and team buildingThe role of the CMO in biotech financingExternal communicationsProfessional development For more information, click here.

The Case for Sites Using Their Own Tech to Accelerate Research and Reduce Burden Jan 20, 2022

Show notes

About the Episode: In this podcast, we discuss the topic of clinical sites shifting to using the own technologies in sponsored trials and how it can advance (and maintain the pace of) clinical research. Our guest, Bryan Spielman, Chief Growth Officer at Advarra lays out the current burden being faced by performing sponsor trials. Mr Spielman also talks about the work Advarra has led in bringing together sites, CROs and sponsors to brainstorm new solutions, and the path forward to encourage wider conversation, acceptance and adoption. Key Takeaways: Identifying current burdens faced by sitesUnderstanding current attitudes towards site-owned technologySteps forward to benefit both sides of clinical research About the Speaker: Bryan Spielman, MBA, is Chief Growth Officer at Advarra and is responsible for driving Advarra’s corporate strategy, mergers and acquisitions, strategic partnerships, and corporate marketing. Spielman brings over 25 years of business development and corporate strategy experience from leading technology companies including those with a focus on life sciences. For more information about innovation in clinical research, click here.

5 Talks to Watch (and Why) at IO360º 2022 with Strategic Advisor Dr Dan Chen Jan 18, 2022

Show notes

About the Episode: Daniel Chen, MD, PhD, Immuno-Oncology 360º 2022 Strategic Advisor, Physician Scientist, Cancer Immunotherapy and Board of Directors, Society for Immunotherapy of Cancer (SITC) and co-author of the Cancer Immunity Cycle, discusses five talks he is excited for, and why, at the upcoming Immuno-Oncology360 conference. The 2022 summit will be held March 16th through the 18th, 2022 at the New York Marriott Brooklyn Bridge. For more information, and the full agenda, visit www.io360summit.com. 5 Top Topics To Watch from Dan Chen: ctDNA Guiding Adjuvant ImmunotherapyClinical Data on PSMA BiTeNovel Approaches to Expand the Therapeutic Index of T cell EngagersSynthetic BiologyIO360° Debate: NK-Cars vs T cell- CARs

8th Annual Immuno-Oncology 360° Summit: What to Expect in 7 Minutes Jan 02, 2022

Show notes

This 7 minute podcast summarizes what you can expect at the 8th annual Immuno-Oncology 360° conference. IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers. Keynotes include: Dr Gregg Semenza, Johns Hopkins University School of MedicineDr Rachel Haurwitz, Caribou BiosciencesDr Christine Brown, City of HopeDr Suzanne Topalian, Johns Hopkins UniversityDr Andrew Baum, Citi Key topic areas include: Discovery/Preclinical ScienceCell & Gene TherapyTranslational ScienceBispecificsClinical DevelopmentsNeoadjuvant/Adjuvant DataEmerging BiomarkersCytokinesClinical OperationsIO CombinationsImaging AdvancementsBusiness Developments The conference takes place February 16-18, 2022 at the New York Marriott Brooklyn Bridge, New York City, NY. For more information please visit www.io360summit.com or contact us at service@tcfllc.org

Patients as Partners EU 2022 in 5 Minutes Dec 17, 2021

Show notes

Conference Producer, Mark Scherzer, talks through what to expect at the upcoming Patients as Partners EU virtual conference taking place 24-25 January 2022. The 6th annual conference will bring together pharma, biotech, CROs and technologists to figure out how to advance patient involvement in medicines development. Experts from Novartis, Pfizer, Merck, EMD Serono, Janssen, Johnson & Johnson, GSK, Ipsen, UCB, Takeda, AbbVie, Noema Pharma, Gilead Sciences, and Pierre Fabre will gather with patient advocacy to address: Outcome measures that matter most to patients Patient Experience Data for regulatory submissionsCompliance barriers to advance patient involvementIncreasing diversity in clinical researchPatient involvement in Turkey and Eastern EuropeImpacting clinical research through carer InputPatient involvement in the design and execution of platform trialsPatient access to research through digital innovation

How Artificial Intelligence Is Creating Better Clinical Trials, with Saama Dec 03, 2021

Show notes

About the Episode: How can artificial intelligence maintain the pace of clinical trials from the COVID-19 pandemic to bring therapeutics to patients faster? Suresh Katta, CEO and founder of Saama Technologies, sits down to discuss exactly how artificial intelligence can be utilized to design better trials from the start, reduce costs and benefit patients and pharma in the long run. Key Takeaways: How to create broader adoption and change management of new technologiesCreating the best protocol design from the start, without pricey and time-consuming amendmentsHow AI can reduce costs, as well as timelines About the Speaker: Suresh Katta founded Saama Technologies in 1997, well before the collective global corporate conscience was aware of the extraordinary opportunities – and significant challenges – inherent in big data. He is a frequent contributor to industry publications and a featured speaker at industry conferences. He earned his M.S. in Computer Engineering at the University of Southwest Louisiana, and his B.S. in Electronics Engineering at the University of Bangalore. For more information: About disruptive innovations in clinical research, click here. For more information about PharmaTalk Radio, visit theconferenceforum.org.

Making the Leap from IV to Subcutaneous, with Halozyme's ENHANZE® Technology Nov 23, 2021

Show notes

About the Episode: How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations. Key Takeaways: How switching to a SC delivery model impacts patients, healthcare providers and drug development companies Keys to successful partnerships and collaborations How Halozyme's ENHANZE® technology enables the shift from IV to SC About the Speaker: Finn Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme. Ms Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did postgraduate research at MIT/Harvard. For more information: About drug delivery and partnerships, click here. For more information about PharmaTalk Radio, visit theconferenceforum.org.

J&J Vision on Progress in Eyecare and Meeting the Needs of Future Patients Oct 21, 2021

Show notes

About the Episode: What does the future of eyecare look like? How does a global company stay innovative? Listen to this podcast to hear Dr Xiao-Yu Song, Johnson & Johnson Vision, providing the latest information on J&J Vision's new products, and her approach to innovation. Key Takeaways: How to encourage innovation in a large, global company What the current and future eyecare needs are How Johnson & Johnson Vision is expanding and innovating their products, including a first-in-class drug delivery contact lens About the Speaker: Xiao-Yu Song is the Global Head of Research & Development for Johnson & Johnson's eye health business. She has overall R&D responsibility for new product development and life cycle management support as well as portfolio management and innovation governance across all platforms in Johnson & Johnson Vision. Xiao-Yu earned her Ph.D. in Biology from the University of North Carolina at Chapel Hill, her M.S. in Biochemistry and Medical Degree at China Medical University, and completed postdoctoral training in autoimmunity and immunology at the U.S. National Institutes of Health. For more information: About disruptive innovation in clinical research, click here. About drug delivery and partnerships, click here. For more information about PharmaTalk Radio, visit theconferenceforum.org.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected